Rationale Accurate prediction of mortality helps select patients for interventions aimed 71 at improving outcome. 72
Objectives Because chronic obstructive pulmonary disease is characterized by low-73 grade systemic inflammation, we hypothesized that addition of inflammatory biomarkers 74 to established predictive factors will improve accuracy. 75
Methods 1843 patients enrolled in the ECLIPSE study were followed for 3 years. 76
Kaplan-Meier curves, log rank analysis and Cox proportional hazards analyses 77 determined the predictive value for mortality of clinical variables, while C-statistics 78 assessed the added discriminative power offered by addition of biomarkers. 79
Measurements At recruitment we measured anthropometrics, spirometry, 6 minute 80 walk distance, dyspnea, BODE index, history of hospitalization, co-morbidities and CT 81 scan emphysema. White blood cell and neutrophil counts, serum or plasma levels of 82 fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein , Clara cell 83 secretory protein-16, Interleukin-6 and -8 and tumor necrosis factor alpha were 84 determined at recruitment and subsequent visits.. 85
Main Results 168 of the 1843 patients (9·1 %) died. Non-survivors were older, had 86 more severe airflow limitation, increased dyspnea, higher BODE score, more 87 emphysema, and higher rates of co-morbidities and history of hospitalizations. The best 88 predictive model for mortality using clinical variables included age, BODE and 89 hospitalization history (C-statistic of 0·686, p<0·001). One single biomarker (Interleukin-90 6) significantly improved the C statistic to 0.708, but this was further improved to 0·726, Chronic obstructive pulmonary disease (COPD) is currently the 4th highest cause of 117 death in the world, and it is predicted to be the 3rd by the year 2020.(1) Accurate 118 prediction of mortality is important because it helps identify patients in whom the 119 implementation of specific therapeutic measures can improve outcome. Several 120 variables that predict mortality have been identified in COPD, including the severity of 121 airflow limitation as measured by the forced expiratory volume in one second (FEV 1 ) , (2) 122 the presence of arterial hypoxemia or hypercapnia(3), exercise performance,(4, 5) 123 degree of breathlessness,(6) and a low body mass index (BMI)(7) . Their integration into 124 multi-dimensional indices such as the BODE (BMI, FEV 1 , dyspnea, and 6 minute walk 125 distance [6MWD])(8) and the ADO (age, dyspnea and FEV 1 )(9) for mortality or the 126 DOSE (dyspnea, FEV 1 , smoking status, and frequency of exacerbations)(10) for 127 exacerbations have been shown to predict outcome better than any of the individual 128 variables by themselves. This likely reflects the fact that COPD is a complex, 129
heterogeneous disease with pulmonary and extra-pulmonary manifestations (11, 12) 130 that are not captured by a single variable. So far all predictive variables in COPD, either 131 alone or in combination, are clinical in nature. Because COPD is also a complex and 132 heterogeneous disease at the genetic, cellular, and molecular level, it is likely that the 133 predictive accuracy of clinical measures can be extended with the use of biomarkers 134 that reflect pathobiological pathways that may be altered in this disease, as has been 135 shown in cardiovascular diseases (13 
Study design 155
The study design of ECLIPSE (Clinicaltrials.gov identifier NCT00292552; GSK study 156 code SCO104960) has been published previously (20) . Briefly, ECLIPSE is an 157 observational, longitudinal and controlled study where, after the baseline visit, 158 participants were evaluated at 3 months, 6 months and then every 6 months for 3 years. 159
In this report we present the longitudinal analysis of mortality using the clinical and 160 biomarker data obtained at baseline. Death was determined up to day 1060 of the study. 161
All cause mortality was used as the outcome; no attempts were made to determine 162 cause of death. ECLIPSE complies with the Declaration of Helsinki and Good Clinical 163
Practice Guidelines, and has been approved by the ethics committees of the 164 participating centers. All participants provided written informed consent prior to the 165 performance of all study related assessments. 166
Patients 168
ECLIPSE studied 2164 patients with COPD (GOLD stage II to IV), 337 smoking controls 169 and 245 non-smoking controls. The current analysis includes only the patients with 170
COPD who had full biomarker data. Inclusion criteria were as follows: male/female 171 subjects aged 40 to 75 years, baseline post-bronchodilator FEV 1 <80% of the reference 172 value and FEV 1 /FVC (Forced Vital Capacity) of ≤0·7; and, current or ex-smokers with a 173 smoking history of ≥10 pack-years. Key exclusion criteria were the presence of a 174 respiratory disorder other than COPD, other significant inflammatory diseases, or a 175 recruited from the outpatient clinics of the participating centers. 177
Measurements 179

Clinical characterization 180
All methods have been described in the baseline and protocol(20, 21) ECLIPSE 181 manuscripts. In summary the American Thoracic Society (ATS) respiratory 182 questionnaire, the modified Medical Research Questionnaire (mMRC) and the COPD-183 specific version of the St. George's Respiratory Questionnaire (SGRQ-C) were used to 184 record clinical data. Exacerbations requiring treatment with antibiotics, oral 185 corticosteroids, and/or hospitalization in the year prior to the study were also recorded. 186
Co-morbidities were self-reported and registered using the ATS-DLD-78 questionnaire. 187 
Role of the funding source 239
The study was sponsored by GlaxoSmithKline. A Steering Committee and a Scientific 240
Committee comprising in total eleven academics and five representatives of the sponsor 241 developed the original study design and concept, the plan for the current analyses, 242 approved the statistical plan, had full access to the data, and were responsible for 243 
Clinical data 249
The consort diagram of the COPD patients included in this study is shown in figure 1. Of 250 the 2164 patients enrolled in ECLIPSE, complete clinical and biomarker data were 251 available in 1843 of them (85·2%), 168 of whom (9·1%) died during follow-up. The 252 clinical characteristics of the patients excluded from the analysis because of incomplete 253 biomarker data were similar in anthropometrics, lung function, walking distance, degree 254 of CT emphysema but had slightly worse BODE index, SGRQ scores and oxygen 255 saturation. 256 Table 1 compares the baseline clinical and physiological characteristics of survivors and 258 non-survivors. The latter were older, had more severe airflow limitation, reported more 259 dyspnea, had a lower 6MWD, had more emphysema by CT scan, a higher BODE score 260 and more co-morbidities. By contrast, gender, smoking status, and BMI were not 261 different between these two groups. Kaplan-Meier analysis showed differences in 262 survival for different age groups, BODE index groups and the incidence of 263 hospitalization due to exacerbations of COPD in the year prior to the study (figure 2). 
Biomarker data 271
The levels of the biomarkers determined in the study were higher in non-survivors (table 272 1). This was not the case for TNFα, the levels of which were not significantly different 273 between groups (results not shown). However, most patients had undetectable low 274 levels of TNFα. 275
Kaplan-Meier survival analysis confirmed that patients with values that were higher than 276 the median value obtained in the control subjects in ECLIPSE of IL-6, CCL-18/PARC, 277 fibrinogen, CRP, and SP-D, but not CC-16, were less likely to survive at the end of three 278 years (p<0·001 by log rank test; figure 3). 279
280
Cox regression analysis (table 2) (table 2) were considered, with two exceptions. As the correlation 289 between WBC and neutrophils was extremely high (Rho=0.92), neutrophils were 290 excluded. Likewise, due to incomplete data for CCL-18 (n=1569), this marker was also 291 excluded from the main analysis. 292 F o r R e v i e w O n l y Table 3 shows how the addition of biomarkers improves the predictive value of the 294 baseline clinical model using C-statistics. The C-statistic value of the clinical model 295 alone (age, BODE, and hospitalizations) was 0·686. The individual addition of the 296 biomarkers discussed above did improve the predictive value (C statistic) of the 297 combined index, but their contribution was relatively small (table 3) , with only IL-6 298 significantly improving the C statistic on its own. By contrast, when all these biomarkers 299
were added together as a panel, the improvement in predictive value (C statistic=0·726) 300 was statistically significant. In the subset of N=1579 subjects with all biomarkers 301 including CCL-18, the results were similar to the main analysis. CCL-18 behaved 302 similarly to most individual biomarkers, and contributed as part of the full biomarker 303 panel to an improvement in predictive value (C statistic =0.697 in the clinical model and 304 0.742 in the full model), which was also statistically significant. The C statistic values 305 were similar when the cohort was split into two subgroups ( This prospective study in a large and well characterized cohort of patients with 312 moderate to very severe COPD provides two important findings: (1) the level of several 313 inflammatory biomarkers determined at recruitment was significantly higher in non-314 survivors over the three years of the study; and, (2) the addition of a selected panel of 315 biomarkers to a model that includes well established clinical factors improves 316 significantly the risk stratification for all-cause mortality in these patients. 317 318
Previous studies 319
Over the past few years there has been a growing interest in the field of biomarkers in 320 provided by the C statistic has not been related to precise clinical metrics. However, the 370 magnitude of the additional predictive power for mortality provided by the biomarkers in 371 this study is similar to that described recently in patients with cardiovascular disease 372 using different biomarkers.(13) 373
Strengths and limitations 375
The large sample size and multi-center nature of the cohort studied, its careful clinical, 376 radiological, functional and biological characterization, and its prospective design and 377 long follow-up time are clear strengths of this study. However, several potential 378 limitations deserve comment. First, there was no adjudication committee to specify the 379 studies showed that the cause of death can be attributed wrongly if it relies exclusively 382 on the death certificate. However, for the health care provider, it is still important to be 383 able to predict all cause mortality risk and evaluate the potentially modifiable factors to 384 help guide individual patient management and therapeutic approaches. Secondly, the 385 panel of biomarkers selected did not include some that have been thought to be 386 important in the pathobiology of COPD, such as the metalloproteinases and growth 387 factors(36). This does not negate the value of our findings, and actually provides room 388 to improve accuracy if in due time, these other biomarkers also are shown to relate to 389 poor outcome. Third, the same could be said about the number of co-morbidities and 390 their relationship to a poor outcome. This also provides room for future studies aimed at 391 discerning the influence of co-morbidity on biomarker levels and their relationship to the 392 risk of death. Fourth, it could be argued that there was no derivative and validating 393 cohort. However, this is customary for non-validated biomarkers whereas in this study 394 we compared validated clinical and serum biomarkers modeled on studies in the 395 cardiovascular arena. Fifth, although the C statistic is the method most commonly used 396 to assess model discrimination, its utility for the evaluation of biomarkers as risk 397 predictors has been questioned. This is because significant increases in the C statistic 398 require very large independent associations of the marker with the outcome of interest. 399
Thus, the significant increments in the C statistic observed in the present study ( 
Conclusions 411
The addition of white blood cell counts and the systemic levels of IL-6, CRP, IL-8, 412
fibrinogen, CCL-18, and SP-D improve significantly the ability of clinical variables to 413 predict mortality in patients with COPD. 414 Table 2 . To test the validity of the model, we divided the cohort into two groups. Patients were matched on age (+/-2 years) and BODE (+/-1 unit). This captured 863 per subgroup (1726 total). The remaining unmatched 117 patients were assigned to one or another group randomly and the analysis on the subgroups was re-run. The table below shows the results. The results are consistent across the two subgroups with C statistic values that are similar in the group as a whole and in the two subgroups. 
